Wednesday, September 12, 2018 1:29:38 PM
Today's press release:
This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention. The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study. As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018. The AHA has not been provided any advanced access to the results of this study.
Notice they stated that the AHA has NOT yet seen the results of the study. Notice that it did not state that Amarin hasn't seen it like JT has said in the past. To push to present at the AHA w/ knowledge of the result is a positive as they would not be in a hurry if it was negative. Also, you can not provide advanced access to the results if you don't have it. You'd simply say we still do not have the results.
Essentially we know they have the results. The question is whether they completely understand it and that is the sole reason why it has not been PR'ed yet. I could be reading into something that isn't there or wasn't intentional but the way its written subtly implies they have it and by PR'ing their push to present it asap, reflects what is likely a positive outcome.
Recent A News
- Agilent Presents 2024 Darlene Solomon Award to University of Cambridge Researcher Joycelyn Tan • Business Wire • 03/14/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 06:08:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 05:05:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 03:04:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 08:41:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 07:05:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 07:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 07:02:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:05:02 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 07:13:03 PM
- Agilent Presents Solutions Innovation Research Awards to Drexel University and Prairie View A&M University Researchers • Business Wire • 02/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:06:38 PM
- Agilent Reports First-Quarter Fiscal Year 2024 Financial Results • Business Wire • 02/27/2024 09:05:00 PM
- Agilent Announces Cash Dividend of 23.6 Cents per Share • Business Wire • 02/21/2024 09:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:15:12 PM
- Agilent CEO Mike McMullen to Retire; Agilent CrossLab Group President Padraig McDonnell Named CEO-Elect • Business Wire • 02/21/2024 09:12:00 PM
- Agilent Ranked Among Top 50 Most Just Companies in America • Business Wire • 02/13/2024 03:11:00 PM
- Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products • Business Wire • 02/08/2024 01:00:00 PM
- Agilent to Participate in TD Cowen Health Care Conference • Business Wire • 02/07/2024 04:20:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/02/2024 01:10:48 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 02/02/2024 01:00:24 PM
- Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology • Business Wire • 01/30/2024 01:00:00 PM
- Agilent to Announce First-Quarter Fiscal Year 2024 Financial Results Feb. 27 • Business Wire • 01/25/2024 05:29:00 PM
- Agilent Announces New ProteoAnalyzer System • Business Wire • 01/16/2024 01:00:00 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM